文献速递消化系统肿瘤

循环肿瘤DNA检测在非转移性结直肠癌术后监测中的预后价值

Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究纳入58例在瑞典4家医院接受根治性手术的I-III期结直肠癌患者,评估系列循环肿瘤DNA(ctDNA)检测是否较常规术后监测更早发现疾病复发。结果显示ctDNA阳性者复发率77%(10/13),ctDNA阳性较影像学和临床证据提前中位3个月;随访期间ctDNA持续阴性的45例患者无一复发(0%;95% CI,0%-7.9%)。

要点

  • ctDNA阳性患者复发率为77%(10/13),阳性结果较常规监测提前中位3个月发现复发。
  • ctDNA持续阴性的45例患者随访中位49个月无一复发(0%;95% CI,0%-7.9%)。
  • 48例未复发患者中3例(6%;95% CI,1.3%-17%)曾出现ctDNA阳性,随后降至检测不到水平。

核心结论

  • 这些发现需在更大规模的前瞻性试验中验证,提示ctDNA分析可作为分诊检测,辅助常规监测策略,根据疾病复发风险对根治性切除后的结直肠癌患者进行分层。

研究设计与样本

  • 本研究纳入58例I、II或III期结直肠癌患者,2007年2月2日至2013年5月8日在瑞典4家医院接受根治性手术切除。
  • 18例患者由对ctDNA结果不知情的临床医生决定接受辅助化疗。
  • 术后1个月及此后每3至6个月采集血样进行ctDNA分析,随访至检出异时性转移或中位49个月。
  • 数据分析时间为2009年3月1日至2018年6月23日。

主要发现

  • 研究纳入58例患者的319份血样,中位(范围)年龄69(47-83)岁,男性34例(59%)。
  • ctDNA阳性患者的复发率为77%(10/13)。
  • ctDNA阳性较影像学和临床复发证据提前中位3个月。
  • 随访期间ctDNA持续阴性的45例患者无一复发(0%;95% CI,0%-7.9%),中位随访49个月。
  • 48例未复发患者中3例(6%;95% CI,1.3%-17%)出现ctDNA阳性结果,随后在随访中降至检测不到水平。

关键数值与推荐

  • 主要结局指标为ctDNA阳性检测疾病复发的敏感性和时机,与常规监测手段(计算机断层扫描和血清癌胚抗原检测)进行比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出这些发现需在更大规模的前瞻性试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with resected, nonmetastatic colorectal cancer (CRC), the optimal surveillance protocol remains unclear. OBJECTIVE: To evaluate whether serial circulating tumor DNA (ctDNA) levels detected disease recurrence earlier, compared with conventional postoperative surveillance, in patients with resected CRC. DESIGN, SETTING, AND PARTICIPANTS: This study included patients (n = 58) with stage I, II, or III CRC who underwent radical surgical resection at 4 Swedish hospitals from February 2, 2007, to May 8, 2013. Eighteen patients received adjuvant chemotherapy at the discretion of their clinicians, who were blinded to the ctDNA results. Blood samples were collected at 1 month after the surgical procedure and every 3 to 6 months thereafter for ctDNA analysis. Patients were followed up until metachronous metastases were detected, or for a median of 49 months. Data analysis was performed from March 1, 2009, to June 23, 2018. MAIN OUTCOMES AND MEASURES: Sensitivity and timing of ctDNA positivity were compared with those of conventional surveillance modalities (computed tomographic scans and serum carcinoembryonic antigen tests) for the detection of disease recurrence. RESULTS: This study included 319 blood samples from 58 patients, with a median (range) age of 69 (47-83) years and 34 males (59%). The recurrence rate among patients with positive ctDNA levels was 77% (10 of 13 patients). Positive ctDNA preceded radiologic and clinical evidence of recurrence by a median of 3 months. Of the 45 patients with negative ctDNA throughout follow-up, none (0%; 95% CI, 0%-7.9%) experienced a relapse, with a median follow-up of 49 months. However, 3 (6%; 95% CI, 1.3%-17%) of the 48 patients without relapse had a positive ctDNA result, which subsequently fell to undetectable levels during follow-up. CONCLUSION AND RELEVANCE: Although these findings need to be validated in a larger, prospective trial, they suggest that ctDNA analysis could complement conventional surveillance strategies as a triage test to stratify patients with resected CRC on the basis of risk of disease recurrence.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Li L, Cohen JD, et al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol. 2019. PMID: 31070668. doi:10.1001/jamaoncol.2019.0512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。